EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC 4.0

Validation of plasma biomarker immunoassay‐based models for predicting brain amyloid positivity in cognitively impaired individuals

Jeremy A Syrjanen, Daniel J Figdore, Michael E Griswold, Heather J Wiste, Ross A Dierkhising, Walter K Kremers, Christian Lachner, Neill R Graff-Radford, Gregory S Day, Jonathan Graff-Radford, Clifford R Jack, David S Knopman und 4 weitere

Alzheimer's & Dementia · 2026-11 · 22 (11)

DOI: 10.1002/alz.71946 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Alzheimer's & Dementia, online erschienen am 04.11.2026. Verfasst von Jeremy A Syrjanen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, tau Proteins, Peptide Fragments, Brain. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, Johnson & Johnson Pharmaceutical Research and Development LLC., CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Combining Alzheimer's disease blood biomarkers may improve prediction of amyloid positivity (A+) compared with single biomarkers. METHODS Logistic regression models using plasma phosphorylated tau 217 (p‐tau217), amyloid beta (Aβ) 42, and Aβ40 were developed in cognitively impaired (CI) participants from Mayo Clinic Rochester (MCR) and validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) and Mayo Clinic Florida (MCF) cohorts. Performance was measured by area under the curve (AUC) and Probability of Amyloid Positivity Score (PAPS). RESULTS Plasma p‐tau217 alone showed high AUC (95% confidence intervals) across cohorts MCR, 0.928 (0.900–0.953); ADNI, 0.938 (0.915–0.959); MCF, 0.935 (0.893–0.970). Adding Aβ42 to regression models yielded marginal model improvement MCR, 0.940 (0.915–0.963); ADNI, 0.945 (0.922–0.965); MCF, 0.960 (0.925–0.986). Utilization of two cutpoints (≥ 90% sensitivity and specificity), yielded ≤ 10% intermediate results for p‐tau217, and ≤ 8% for p‐tau217+Aβ42. Addition of Aβ40 did not improve models’ performance. DISCUSSION An immunoassay‐based p‐tau217 PAPS model accurately predicted amyloid positivity across independent CI cohorts and achieved confirmatory‐test performance with two cutpoints. The added value of Aβ42 was modest and cohort dependent, supporting the potential of use of p‐tau217–based PAPS in clinical workflows.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-Peptidestau ProteinsPeptide FragmentsBrainAlzheimer DiseaseCognitive DysfunctionHumansFemaleBiomarkersImmunoassayMaleAgedAged, 80 and overPredictive Value of TestsLogistic Models

Stichwörter der Autor:innen

Alzheimer's disease pathologycognitively impairedplasma p‐tau217probability of amyloid positivity scores

Substanzen

Amyloid beta-PeptidesBiomarkerstau ProteinsPeptide Fragmentsamyloid beta-protein (1-40)amyloid beta-protein (1-42)

Autor:innen und Institutionen

  • Mayo Clinic, Rochester, Minnesota, USA.
  • University of Mississippi Medical Center, Jackson, Mississippi, USA.
  • Mayo Clinic, Jacksonville, Florida, USA.

ORCID-Profile: Alicia Algeciras-Schimnich

Förderung

  • NIA NIH HHS
  • Johnson & Johnson Pharmaceutical Research and Development LLC.
  • CIHR
  • Lumosity
  • Araclon Biotech
  • Eli Lilly and Company
  • NeuroRx Research
  • Janssen Alzheimer Immunotherapy Research and Development LLC

Zitieren

APA

Syrjanen, J. A., Figdore, D. J., Griswold, M. E., Wiste, H. J., Dierkhising, R. A., Kremers, W. K., Lachner, C., Graff-Radford, N. R., Day, G. S., Graff-Radford, J., Jack, C. R., Knopman, D. S., Petersen, R. C., Bornhorst, J. A., Algeciras-Schimnich, A., & Alzheimer's Disease Neuroimaging Initiative (2026). Validation of plasma biomarker immunoassay‐based models for predicting brain amyloid positivity in cognitively impaired individuals. Alzheimer's & Dementia, 22(11). https://doi.org/10.1002/alz.71946

Vancouver

Syrjanen JA, Figdore DJ, Griswold ME, Wiste HJ, Dierkhising RA, Kremers WK, et al. Validation of plasma biomarker immunoassay‐based models for predicting brain amyloid positivity in cognitively impaired individuals. Alzheimer's & Dementia. 2026;22(11). doi:10.1002/alz.71946

BibTeX
@article{Syrjanen2026,
  author = {Syrjanen, Jeremy A and Figdore, Daniel J and Griswold, Michael E and Wiste, Heather J and Dierkhising, Ross A and Kremers, Walter K and Lachner, Christian and Graff-Radford, Neill R and Day, Gregory S and Graff-Radford, Jonathan and Jack, Clifford R and Knopman, David S and Petersen, Ronald C and Bornhorst, Joshua A and Algeciras-Schimnich, Alicia and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
  title = {Validation of plasma biomarker immunoassay‐based models for predicting brain amyloid positivity in cognitively impaired individuals},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {11},
  doi = {10.1002/alz.71946}
}
Kostenlos starten →